angiographic iodinated contrast agent A

Angiographic iodinated contrast agent A is a placeholder designation for one of two licensed iodinated contrast media evaluated in a Phase 4 clinical trial (NCT00107224) sponsored by NHS Tayside and the University of Dundee. The study, titled "Comparison of two angiographic contrast agents for prevention of contrast-induced nephropathy," compared the safety profiles of an iso-osmolar contrast agent (**iodixanol**, brand name Visipaque) and a low-osmolar contrast agent (**iohexol**, brand name Omnipaque). The primary objective was to determine which agent better reduces the incidence of contrast-induced nephropathy (CIN) or acute kidney injury (AKI) in adults undergoing routine peripheral or renovascular angiography, based on renal function measurements 48–72 hours post-procedure. Iodinated contrast agents are diagnostic tools that enhance the visibility of vascular structures during X-ray-based imaging by absorbing X-ray photons.

Other names

angiographic iodinated contrast agent A